Design and Evaluation of Floating Dosage Forms as Controlled Release Modules

Abstract

Human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS), commonly referred to as HIV/AIDS, constitute one of the most serious infectious disease challenges to public health globally, and has had a crippling effect in certain parts of the world. There are currently 33.2 million people living with HIV/AIDS globally. newlineThe people suffering with HIV infection need to take more number of drugs with repeated administration. This is because of the structural changes of the viral gene inside the cell and less biological half lives of these drugs. This causes the patient non compliance and some time may lead to the severe adverse affects. Sustaining the drug release of these drugs may improve the patient compliance, reduce the plasma drug fluctuations and limit the adverse reactions. newlineIn the present study five anti retroviral drugs such as Stavudine, lamivudine, Lopinavir, Ritonavir and Valganciclovir were selected to develop the extended release formulations using various rate controlled polymers such as Lipoidal carriers, Methylacrylates and Polyethylene oxides. newlineIn the present proposed work lipid based controlled release dosage forms of selected antiretro viral drugs are designed employing novel floating system technology. The hydrodynamically balanced systems without the effervescent components are designed and compared with effervescent systems. Both single and multi unit dosage forms are designed and evaluated for the desired parameters. Different polymers and polymer combinations are employed with various Lipoidal excipients differing in their hydrophilic and lipophilic properties to evaluate their suitability for floating systems.